Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacoinvasive Therapy With Prourokinase for STEMI
NCT01642667Phase 3Completed
- Sponsor
- Suzhou Landing Biopharmaceutical
- Start
- Nov 2008
- Primary completion
- Nov 2009
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human prourokinase in ST-segment elevation myocardial infarction (STEMI), sponsored by Suzhou Landing Biopharmaceutical. Started Nov 2008; status: completed.
02
Drugs
recombinant human prourokinase
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT01642667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01642667.